Revolution Medicines to Submit Pancreatic Cancer Drug for FDA Approval
Mark Goldsmith, CEO of Revolution Medicines, has announced the upcoming submission of daraxonrasib for FDA approval as the company begins shipping the experimental drug.
Editorial Staff
1 min read
Updated 10 days ago
Revolution Medicines is set to ship its experimental drug, daraxonrasib, aimed at treating pancreatic cancer. The announcement comes from CEO Mark Goldsmith.
Goldsmith indicated that the company plans to submit the drug for FDA approval in the near future, although specific timelines have not been disclosed.
This development marks a significant step in the company's efforts to address pancreatic cancer, a disease known for its challenging prognosis.